Importantly, they showed that administration of a sEV release inhibitor or implantation of cancer cells that release a limited amount of sEVs (mEERL Rab27a+/- and Rab27b-/- cells) attenuated the development of pain, thus providing convincing evidence for a significant role of cancer sEVs in pain. Here, RAB27A is linked to cancer.